Comparative Efficacy, Safety, and Costs of Sorafenib vs. Sunitinib as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis-Reference-Cited by-同舟云学术

Comparative Efficacy, Safety, and Costs of Sorafenib vs. Sunitinib as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

Published:2019-06-21 Issue: Volume:9 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Deng Huan,Liu Wenfeng,He Ting,Hong Zhengdong,Yi Fengming,Wei Yiping,Zhang Wenxiong

Funder

National Natural Science Foundation of China

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference30 articles.

1. Cancer statistics, 2019;Siegel;CA Cancer J Clin.,2019

2. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma;Wersäll;Radiother Oncol.,2005

3. NCCN clinical practice guidelines in oncology: kidney cancer;Motzer;J Natl Compr Canc Netw.,2009

4. Sorafenib in advanced clear-cell renal-cell carcinoma;Escudier;N Engl J Med.,2007

5. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma;Motzer;J Clin Oncol.,2009

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From bench to bedside: the past, present and future of IL-21 immunotherapy;Medical Oncology;2024-06-20

2. Adjuvant immunotherapy for locally advanced renal cell carcinoma;Expert Opinion on Biological Therapy;2023-12-02

3. CPT2-mediated fatty acid oxidation inhibits tumorigenesis and enhances sorafenib sensitivity via the ROS/PPARγ/NF-κB pathway in clear cell renal cell carcinoma;Cellular Signalling;2023-10

4. Sorafenib exhibits lower toxicity and comparable efficacy to sunitinib as a first-line treatment for metastatic renal cell carcinoma: A systematic review and meta-analysis;Medicine;2023-09-08

5. The chromosomal instability 25 gene signature is identified in clear cell renal cell carcinoma and serves as a predictor for survival and Sunitinib response;Frontiers in Oncology;2023-05-01